How it started
Facilities & Expansion
Founded in 2011, Samsung Biologics built four manufacturing plants between 2011 and 2023 with a combined capacity of 605,000 liters. In 2023, Samsung Biologics began construction of a fifth plant in Incheon, South Korea with a capacity of 180,000 liters. In March 2025, Samsung Biologics began operations at its dedicated antibody-drug conjugate (ADC) manufacturing facility in Songdo, expanding its service capabilities into ADC production. With the addition of Plant 5, the company holds a total manufacturing capacity of 785,000 liters.
Since 2020, Samsung Biologics has expanded its United States operations, opening offices in New Jersey and Boston to more closely support U.S. biopharmaceutical companies across both coasts. In 2025, Samsung Biologics also opened a regional office in Tokyo, Japan, to strengthen ties with Japanese pharmaceutical and biotechnology companies. In 2025, Samsung acquired the Human Genome Sciences drug production facilities based in Rockville, Maryland from GSK plc for $280 million to establish their first US production site.
In 2025, Samsung Biologics launched ExellenS™, a manufacturing framework based on the company's experience in plant design, digitalization, and operations. The framework standardizes equipment, processes, and functional specifications to facilitate technology transfers, regulatory approvals, and production outcomes. Samsung Biologics uses the ExellenS™ model to maintain consistency across its manufacturing operations.
Notable Partnerships
As of June 2024, Samsung Biologics' CEO John Rim reported active partnerships with 16 of the top 20 largest biopharmaceutical companies. This includes early deals with Roche and Bristol-Myers Squibb in 2013, through to large partnerships during and after the pandemic. In 2020, GSK and Samsung Biologics signed the first of two major agreements: a $231 million, eight-year deal to manufacture biological therapies, including the lupus drug Benlysta. Two years later, a second $296 million deal was signed.
From Wikipedia’s article on Samsung Biologics, shared under CC BY-SA 4.0.2